Shares of Pfizer Inc. (PFE) got a little boost on Thursday. Why? Because the company shared some pretty encouraging news about a two-drug punch it's testing for prostate cancer. The combo—Talzenna plus Xtandi—just hit its main goal in a big late-stage trial.

Here’s the deal. The trial, called TALAPRO-3, was for men with a specific type of advanced prostate cancer that’s still sensitive to hormone therapy and has mutations in genes involved in a DNA repair pathway called homologous recombination repair (HRR). The main thing researchers were watching was how long patients could go without their cancer getting visibly worse on scans—what’s called radiographic progression-free survival (rPFS).

The result? Adding Talzenna to the standard treatment, Xtandi, led to a “statistically significant and clinically meaningful improvement” in rPFS compared to patients who just got Xtandi with a placebo. And it wasn’t just a squeaker. The benefit “markedly exceeded” the target the study had set ahead of time. At the time they crunched the numbers, most of the patients in the combo group were still progression-free.

Now, the good news didn’t stop there. The combo worked whether patients had mutations in the well-known BRCA genes or in other, non-BRCA HRR genes. That’s important because it suggests the treatment could help a broader group. There was also a “strong trend” toward improving overall survival—the ultimate gold standard—though that data is still early. Benefits popped up in other measures too, like how many patients responded to treatment and how long those responses lasted.

So, what’s next? Pfizer says it will submit this full data set for presentation at a medical conference and start talking with health regulators around the world. The goal is clear: to get this combination approved for use in this earlier stage of prostate cancer. It’s a logical expansion. The Talzenna/Xtandi combo is already approved in about 60 countries, including the U.S., for a later, more treatment-resistant form of the disease.

In a separate bit of good news for Pfizer’s oncology pipeline this week, the company also said a Phase 2 study for a different cancer combo met its goal. That trial, called FOURLIGHT-1, tested a drug called atirmociclib plus fulvestrant in women with pretreated metastatic breast cancer. It showed a significant improvement in progression-free survival, and the benefit was seen across all patient subgroups they looked at. Notably, over 90% of patients in that trial started the new treatment within three months of stopping their prior therapy.

Back to the main event. For investors, this prostate cancer data is a positive step for a company that’s been working to rebuild its pipeline after some high-profile setbacks. The stock reaction was modest—shares were up about 0.1% to $27.35—but every bit of promising clinical news helps. The share price is now flirting with its 52-week high of $27.94.